Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Peter Buch, MD, FACG, AGAF, FACP
Mallik Greene, PhD
Jordan Karlitz, MD
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Shelina Ramnarine, PhD
David A. Johnson, MD, FACG, FACP
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Lajos Pusztai, MD, DPhil
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP
Wassim Mchayleh, MD, MBA, FACP
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Virginia Kaklamani, MD, DSc
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Mohamed Abdelbaki, MD
Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
Gastric Cancer Prevention: A Risk-Based Approach
Chul Hyun, MD, PhD, MPH
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.